Literature DB >> 3923520

Increased or decreased locomotor response in rats following repeated administration of apomorphine depends on dosage interval.

R Castro, P Abreu, C H Calzadilla, M Rodriguez.   

Abstract

Administration of drugs that reduce the influence of dopamine at its receptor site can lead to postsynaptic supersensitivity, whereas treatment with dopamine (DA) agonists can cause postsynaptic subsensitivity. Both unaltered and enhanced postsynaptic responses to DA have been shown after pretreatment with DA agonists. In the present manuscript pretreatment with apomorphine, a dopaminergic agonist, is shown to induce either increased or reduced locomotor activity. When a drug-free period between successive injections was allowed, apomorphine induced an enhanced locomotor response, whereas a reduced response occurred when each dose was injected before the previous apomorphine dose had been completely metabolized. Pretreatment with both high (1 and 3 mg/kg) and low (0.05 mg/kg) apomorphine doses enhanced the response. Apomorphine treatment that caused enhanced locomotor responses did not modify the stereotypy response to the drug. Similar enhanced or reduced response were found in rats with partial lesions of the nigrostriatal system. These altered responses to DA agonists may have important clinical consequences. The present data also suggest the existence of a different DA systems for locomotor and stereotypy actions of dopaminergic agonists.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3923520     DOI: 10.1007/bf00428198

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  47 in total

1.  Alpha-flupenthixol-induced hyperactivity by chronic dosing in rats.

Authors:  B J Sahakian; T W Robbins; S D Iversen
Journal:  Eur J Pharmacol       Date:  1976-05       Impact factor: 4.432

2.  Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization.

Authors:  F Hefti; E Melamed; R J Wurtman
Journal:  Brain Res       Date:  1980-08-11       Impact factor: 3.252

Review 3.  Relationship of the actions of neuroleptic drugs to the pathophysiology of tardive dyskinesia.

Authors:  R J Baldessarini; D Tarsy
Journal:  Int Rev Neurobiol       Date:  1979       Impact factor: 3.230

4.  On the mechanism of presynaptic autoreceptor-mediated inhibition of transmitter synthesis in dopaminergic nerve terminals.

Authors:  M Bitran; G Bustos
Journal:  Biochem Pharmacol       Date:  1982-09-15       Impact factor: 5.858

5.  Amphetamine-induced hypersensitivity in guinea pigs.

Authors:  W J Weiner; C G Goetz; P A Nausieda; H L Klawans
Journal:  Neurology       Date:  1979-07       Impact factor: 9.910

6.  Dopamine receptors in the Parkinsonian brain.

Authors:  U K Rinne; P Lönnberg; V Koskinen
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

7.  Is L-DOPA drug holiday useful?

Authors:  L K Direnfeld; R G Feldman; M P Alexander; M Kelly-Hayes
Journal:  Neurology       Date:  1980-07       Impact factor: 9.910

8.  Differential enhancement of behavioral sensitivity to apomorphine following chronic treatment of rats with (-)-sulpiride and haloperidol.

Authors:  N Montanaro; R Dall'Olio; O Gandolfi; A Vaccheri
Journal:  Eur J Pharmacol       Date:  1982-06-16       Impact factor: 4.432

9.  Subacute L-DOPA in mice: biochemical and behavioural effects.

Authors:  O Jenkins; R Bailey; E Crisp; D M Jackson
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

10.  Long-term facilitation of amphetamine-induced rotational behavior and striatal dopamine release produced by a single exposure to amphetamine: sex differences.

Authors:  T E Robinson; J B Becker; S K Presty
Journal:  Brain Res       Date:  1982-12-16       Impact factor: 3.252

View more
  14 in total

1.  Electrophysiological and morphological evidence for a GABAergic nigrostriatal pathway.

Authors:  M Rodríguez; T González-Hernández
Journal:  J Neurosci       Date:  1999-06-01       Impact factor: 6.167

2.  Effects of selective D1 and D2 dopamine antagonists on the development of behavioral sensitization to apomorphine.

Authors:  B A Mattingly; J K Rowlett; J T Graff; B J Hatton
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

Review 3.  The hormonal signature of energy deficit: Increasing the value of food reward.

Authors:  Sarah H Lockie; Zane B Andrews
Journal:  Mol Metab       Date:  2013-08-19       Impact factor: 7.422

4.  Chronic administration of a selective dopamine D-2 agonist: factors determining behavioral tolerance and sensitization.

Authors:  M T Martin-Iverson; S M Stahl; S D Iversen
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

5.  L-dopa causes an acute, partial and reversible reversal of denervation-induced supersensitivity of striatal dopaminergic receptors.

Authors:  S Ferre; M Casas; A Cobos; C Garcia; F Jane; J M Grau
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

6.  The motor response to sequential apomorphine in parkinsonian fluctuations.

Authors:  A J Hughes; A J Lees; G M Stern
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-04       Impact factor: 10.154

7.  Ontogeny of behavioral sensitization in the rat: effects of direct and indirect dopamine agonists.

Authors:  S A McDougall; M A Duke; C A Bolanos; C A Crawford
Journal:  Psychopharmacology (Berl)       Date:  1994-12       Impact factor: 4.530

8.  Prenatal haloperidol alters the expression of DNA polymerases in brain regions of neonate rats.

Authors:  R Castro; B Brito; V Notario
Journal:  Cell Mol Neurobiol       Date:  1990-06       Impact factor: 5.046

9.  A study of tolerance to apomorphine.

Authors:  J L Montastruc; M E Llau; J M Senard; M A Tran; O Rascol; P Montastruc
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

10.  Enhanced stereotyped response to apomorphine after chronic D-1 blockade with SCH 23390.

Authors:  A Vaccheri; R Dall'Olio; O Gandolfi; P Roncada; N Montanaro
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.